olivLaw · US equity research
Allogene Therapeutics, Inc. ALLO
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
Allogene Therapeutics develops allogeneic 'off-the-shelf' CAR T therapies for cancer and autoimmune disease, with its pivotal ALPHA3 program in first-line large B-cell lymphoma now in focus. The 2026 interim futility analysis showed a higher MRD negativity rate in the cema-cel arm, which keeps investors and specialists watching the program closely.
At the close of 04 Nov 2026, Allogene Therapeutics, Inc. (ALLO) stock was 1.19 USD (+6.25% on the day), with market capitalisation 411.1 m USD, dividend yield 0.00%, beta 1.57, 52-week range 1.05–3.06 USD. Latest reported quarter (Q2 2026): revenue of 4.6 m USD, net income of -42.7 m USD, diluted EPS -0.13 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 36.8
- weak (30–45)
- Bollinger (20, 2)
- 1.10 – 1.46
- in the lower half of the band · %B 0.26 · band width 28.2%
- SMA 50 / 200
- 1.56 / 1.97
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.11 / -0.12
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −20.7% | −1.1% | −19.6 pp | — |
| 3 months | −39.0% | −0.5% | −38.5 pp | — |
| 6 months | −48.5% | +4.4% | −52.9 pp | — |
| Year to date | −13.1% | +12.3% | −25.5 pp | — |
| 1 year | +7.2% | +13.5% | −6.3 pp | +5.3% |
| 3 years | −66.0% | +76.4% | −142.4 pp | −6.6% |
| 5 years | −94.1% | +63.7% | −157.8 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | — | 4.6 m |
| Research & development | 44.7 m | 45.0 m | 50.2 m | 40.2 m | 31.2 m | 28.6 m | 32.0 m | 30.7 m |
| Operating income | -71.8 m | -60.5 m | -65.2 m | -56.8 m | -44.9 m | -42.4 m | -46.1 m | -46.9 m |
| Depreciation & amortisation | 3.2 m ≈ | 3.2 m | 3.1 m | 3.1 m ≈ | 3.1 m ≈ | 3.1 m | 2.9 m | 2.6 m ≈ |
| Interest expense | 100.0 k | 81.0 k | 150.0 k | 268.0 k | 344.0 k | 313.0 k | 300.0 k | 343.0 k |
| Net income | -66.3 m | -59.9 m | -59.7 m | -50.9 m | -41.4 m | -38.8 m | -42.6 m | -42.7 m |
| Diluted EPS | -0.32 | -0.28 ≈ | -0.28 | -0.23 | -0.19 | -0.17 ≈ | -0.18 | -0.13 |
| Operating cash flow | -44.1 m ≈ | -36.7 m | -52.9 m | -39.0 m ≈ | -29.7 m ≈ | -27.6 m | -12.9 m | -32.0 m ≈ |
| Capex | 429.0 k ≈ | 257.0 k | 99.0 k | 44.0 k ≈ | 243.0 k ≈ | 0 | 9.0 k | 150.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | unavailable | 0 | 0 | 114.1 m | 156.0 k | 95.0 k | 22.0 k | 0 |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | −99.9% | −39.1% | −76.8% | −100.0% |
| Net income | -211.5 m | -184.6 m | -316.4 m | -182.1 m | -340.4 m | -327.3 m | -257.6 m | -190.9 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -1.83 | -2.63 | -1.34 | -2.38 | -2.09 | -1.32 | -0.87 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | -159.6% | -218,214.1% | -344,489.5% | -1,170,863.6% | unavailable |
| Free cash flow | -47.9 m | -188.1 m | -181.1 m | -206.3 m | -225.7 m | -239.2 m | -201.0 m | -149.6 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 51.7 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 292.5 m USD
- Total assets
- 415.9 m USD
- Debt / equity
- unavailable
- Current ratio
- 7.93x
- ROE
- -53.4%
- ROA
- -39.6%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 114.1 m | 156.0 k | 95.0 k | 22.0 k | 0 | SEC (XBRL)· 12 Mar 2026verified |
| Research & development | 193.0 m | 220.2 m | 256.4 m | 242.9 m | 192.3 m | 150.2 m | SEC (XBRL)· 12 Mar 2026verified |
| Operating income | -258.2 m | -180.2 m | -335.5 m | -327.7 m | -273.2 m | -209.3 m | SEC (XBRL)· 12 Mar 2026verified |
| Depreciation & amortisation | 7.4 m | 10.5 m | 14.3 m | 14.2 m | 13.6 m | 12.4 m | SEC (XBRL)· 12 Mar 2026verified |
| EBITDA | -250.8 m ≈ | -169.7 m ≈ | -321.2 m ≈ | -313.5 m ≈ | -259.6 m ≈ | -197.0 m ≈ | SEC (XBRL)· 12 Mar 2026derived |
| Interest expense | 0 | — | — | 0 | 181.0 k | 1.1 m | SEC (XBRL)· 12 Mar 2026verified |
| Pre-tax income | -250.2 m | -257.0 m | — | -327.3 m | -257.1 m | -190.9 m | SEC (XBRL)· 12 Mar 2026verified |
| Income tax | 0 | 0 | 0 | 0 | 443.0 k | 0 | SEC (XBRL)· 12 Mar 2026verified |
| Net income | -316.4 m | -182.1 m | -340.4 m | -327.3 m | -257.6 m | -190.9 m | SEC (XBRL)· 12 Mar 2026verified |
| Diluted EPS | -2.63 | -1.34 | -2.38 | -2.09 | -1.32 | -0.87 | SEC (XBRL)· 12 Mar 2026verified |
| Weighted average diluted shares | 120.4 m | 135.8 m | 143.1 m | 156.9 m | 194.8 m | 220.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Dividend per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | SEC (XBRL)· 12 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 183.4 m | 173.3 m | 61.9 m | 83.2 m | 75.2 m | 51.7 m | SEC (XBRL)· 12 Mar 2026verified |
| Current assets | 845.1 m | 471.3 m | 528.8 m | 459.1 m | 303.4 m | 257.7 m | SEC (XBRL)· 12 Mar 2026verified |
| Property, plant & equipment, net | 118.8 m | 123.0 m | 112.8 m | 99.5 m | 86.1 m | 72.8 m | SEC (XBRL)· 12 Mar 2026verified |
| Intangibles (excl. goodwill) | 0 | — | — | — | — | — | SEC (XBRL)· 25 Feb 2021verified |
| Total assets | 1.2 bn | 1.1 bn | 821.6 m | 642.8 m | 548.7 m | 415.9 m | SEC (XBRL)· 12 Mar 2026verified |
| Accounts payable | 10.4 m | 10.3 m | 13.9 m | 5.9 m | 5.4 m | 4.3 m | SEC (XBRL)· 12 Mar 2026verified |
| Current liabilities | 94.3 m | 47.9 m | 53.7 m | 37.1 m | 35.5 m | 32.5 m | SEC (XBRL)· 12 Mar 2026verified |
| Total liabilities | 148.2 m | 125.6 m | 154.7 m | 130.6 m | 126.5 m | 123.4 m | SEC (XBRL)· 12 Mar 2026verified |
| Equity | 1.0 bn † | 925.2 m † | 666.9 m † | 512.2 m † | 422.2 m † | 292.5 m † | SEC (XBRL)· 12 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -115.1 m | -184.8 m | -220.5 m | -237.7 m | -200.3 m | -149.2 m | SEC (XBRL)· 12 Mar 2026verified |
| Capex | 66.0 m | 21.4 m | 5.2 m | 1.5 m | 694.0 k | 386.0 k | SEC (XBRL)· 12 Mar 2026verified |
| Free cash flow | -181.1 m ≈ | -206.3 m ≈ | -225.7 m ≈ | -239.2 m ≈ | -201.0 m ≈ | -149.6 m ≈ | SEC (XBRL)· 12 Mar 2026derived |
| Investing cash flow | -505.1 m | 163.7 m | 106.2 m | 163.3 m | 75.7 m | 95.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Financing cash flow | 633.6 m | 12.0 m | 3.0 m | 95.7 m | 116.7 m | 30.2 m | SEC (XBRL)· 12 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 25.0% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 411.1 m USD
Key indicators
Coverage and freshness
Score by group
25% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the base of the ratio is not positive
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -3,566.7% | 21 (vs peers) | 25% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -138.7x | 0 (on a fixed band) | 25% |
| Current ratio · Balance sheet | 10.7x | 100 (on a fixed band) | 17% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -25.0% | 0 (on a fixed band) | 33% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial21/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Allogene Therapeutics, Inc. (ALLO). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 0 USD in 2025; YoY growth -100.0%; net margin -3,566.7%; ROE -42.4%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 10.7x
What contradicts it
- Net margin: -3,566.7%
- Interest coverage: -138.7x
- FCF yield: -25.0%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 258.8 bn | 27.7 | 78.4% | 24.1% | +10.0% | +39% / +77% |
| GILDGilead Sciences, Inc. | 216.4 bn | — | -22.3% | -12.5% | +2.4% | +39% / +128% |
| MRNAModerna, Inc. | 103.2 bn | — | -39.0% | -141.4% | −39.9% | +895% / +233% |
| RVMDRevolution Medicines, Inc. | 43.2 bn | — | -93.6% | -946.8% | unavailable | +157% / +756% |
| BIIBBiogen Inc. | 37.6 bn | 108.8 | 1.9% | 3.4% | +2.2% | +40% / +9% |
| EXELExelixis, Inc. | 17.8 bn | 21.7 | 44.3% | 35.5% | +7.0% | +65% / +234% |
| NBIXNeurocrine Biosciences, Inc. | 16.8 bn | 24.6 | 20.4% | 19.0% | +21.4% | +9% / +42% |
| HALOHalozyme Therapeutics, Inc. | 14.8 bn | 38.4 | 173.7% | 24.9% | +37.6% | +83% / +238% |
| KYMRKymera Therapeutics, Inc. | 11.6 bn | — | -27.3% | -341.8% | −16.7% | +101% / +556% |
| BEAMBeam Therapeutics Inc. | 2.9 bn | — | -11.3% | -73.9% | +120.0% | +10% / −1% |
| BCRXBiocryst Pharmaceuticals, Inc. | 2.1 bn | — | — | -37.4% | +94.1% | +15% / +40% |
| MAZEMaze Therapeutics, Inc. | 1.9 bn | — | -37.3% | -5,343.6% | unavailable | −12% / unavailable |
| ALVOAlvotech | 1.5 bn | 46.7 | — | 4.8% | +19.7% | −8% / −51% |
| CGEMCullinan Therapeutics, Inc. | 803.8 m | — | -50.3% | — | −100.0% | +10% / +53% |
| CADLCandel Therapeutics, Inc. | 692.5 m | — | -81.8% | — | 0.0% | +90% / +907% |
| FDMT4D Molecular Therapeutics, Inc. | 611.3 m | — | -43.3% | -194.7% | +230,194.6% | +5% / −3% |
| ATYRaTYR PHARMA INC | 606.2 m | — | -98.4% | -32,003.7% | −19.1% | +691% / +375% |
| RGNXREGENXBIO Inc. | 509.0 m | — | -137.6% | -112.6% | +104.5% | −42% / −61% |
| ALLOAllogene Therapeutics, Inc. | 411.1 m | — | -42.4% | -3,566.7% | −100.0% | +7% / −66% |
| AUTLAutolus Therapeutics plc | 367.3 m | — | -133.0% | -238.7% | +644.9% | −2% / −68% |
| FENCFennec Pharmaceuticals Inc. | 362.9 m | — | -18.6% | -5.5% | −6.1% | +26% / +20% |
| AGENAgenus Inc | 313.8 m | 2.6 | — | 69.3% | +10.4% | +53% / −55% |
| OCGNOcugen, Inc. | 296.7 m | — | — | -1,367.6% | +8.8% | −29% / +126% |
| ALECAlector, Inc. | 254.6 m | — | -385.1% | -850.1% | −79.1% | +71% / −58% |
| PLXProtalix BioTherapeutics, Inc. | 216.7 m | 11.7 | 31.2% | 23.5% | −1.2% | +51% / +78% |
1- and 3-year price returns: for ALLO from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Allogene Therapeutics develops allogeneic 'off-the-shelf' CAR T therapies for cancer and autoimmune disease, with its pivotal ALPHA3 program in first-line large B-cell lymphoma now in focus. The 2026 interim futility analysis showed a higher MRD negativity rate in the cema-cel arm, which keeps investors and specialists watching the program closely.2
SWOT
Strengths
- The company has an allogeneic platform with several clinical programs and its own manufacturing facility for clinical supply.1
- Interim ALPHA3 data show a clear difference in MRD clearance, with a safety profile that compares favorably with the broader CAR T experience.23
- FDA RMAT and Fast Track designations may facilitate dialogue with the agency and a faster timeline.
Weaknesses
- The company has no approved products and no product revenue, and its losses are recurring.
- Dependence on external financing is high, and future capital market conditions are uncertain.
- Programs are at early or intermediate stages, and clinical results for some remain limited.
Opportunities
- If ALPHA3 confirms the benefit, MRD-guided consolidation could open a new first-line indication.
- The Dagger technology could extend use into autoimmune disease, where demand for chemotherapy-free treatments is high.
Threats
- If financing is not available on acceptable terms, development could slow or stop.
- Serious adverse events in trials can lead to suspensions or protocol changes, as already happened in one arm.
- Competition in CAR T and autoimmune cell therapies could reduce the potential market share.
Risks
- Capital requirementshigh
The company has no committed financing source, and failing to raise funds could delay or end programs.1
- ALPHA3 trial riskhigh
The interim futility analysis rests on a small sample, and final event-free survival results are not yet known.2
- Operational disruptionmedium
The facility and suppliers, located in areas exposed to earthquakes and fires, could be affected by natural events or other interruptions.1
- Banking system exposurelow
Cash is held in banks above insurance limits, and access to those funds could be delayed in a crisis.1
Investment thesis
What would need to be true (bull case)
- If final ALPHA3 data confirm the benefit of consolidation with cema-cel, the company could become the first CAR T therapy used in first line for patients at high risk of relapse.2
- Immediate availability of an allogeneic product could make administration in community centers, where CAR T experience is limited, more feasible.2
- The Dagger technology could enable autoimmune treatments without chemotherapy, a difference that could matter commercially.
What would break the thesis
- The company may need additional financing before any product revenue, which could lead to significant dilution.
- Interim results are based on a small number of patients, and final efficacy could differ from what is anticipated.
- Competition from approved autologous therapies and other allogeneic programs could limit adoption of the product.
What to watch
- Reaching about 100 active ALPHA3 sites2026
- Interim EFS analysis in ALPHA3mid-2027
- Completion of ALPHA3 enrollment and program financing2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell product candidates, meaning they are derived from healthy donors for use in any patient, unlike autologous therapies. The company has no products approved for sale and has not generated product revenue to date, and its net loss was $190.9 million for 2025.1 Because of this loss record and an accumulated deficit, operations depend on available capital, which stood at $258.3 million on 31 December 2025.1
The platform relies on gene-editing technologies, including TALEN and CRISPR, to reduce the risk of graft-versus-host disease, along with the proprietary Dagger technology aimed at reducing the need for standard chemotherapy lymphodepletion. Clinical results for these approaches are still being validated, so their long-term value remains an open question.1
Segments
Cema-cel (LBCL, first line)
Cema-cel is the most advanced candidate and is being evaluated in the pivotal Phase 2 ALPHA3 trial as consolidation after first-line therapy. At the April 2026 interim futility analysis, 58.3% of patients in the cema-cel arm achieved MRD negativity, compared with 16.7% in the observation arm.2 The study is enrolling at more than 80 sites and could reach about 100 sites by the end of 2026.3
Market context
The CAR T market already includes approved autologous products, and allogeneic therapies aim to gain ground through immediate availability and scalability. If ALPHA3 data confirm the clinical benefit of MRD-guided consolidation, the product could be used in community cancer centers, where many newly diagnosed patients receive care.1 Access to this market, however, depends on final results and regulatory approvals.2
Trends
- Outpatient delivery of CAR Ttailwind
ALPHA3 data suggest that treatment and monitoring can largely take place in the outpatient setting, even at centers with limited CAR T experience.2 If these results hold, they could widen access to cell therapies.
- Capital dependence and dilutionheadwind
The company has no committed source of financing and may need to issue equity or convertible securities, which would dilute shareholders.1 High operating expenses keep this pressure constant.
Competitive position
The company competes with approved autologous CAR T therapies, which have demonstrated efficacy but are limited by manufacturing time and logistical complexity. The allogeneic advantage lies in immediate product availability, and in this context the sources indicate the therapy could be administered more broadly.12
Other developers of allogeneic and cell-based autoimmune therapies may compete for the same patients and development funding. The company acknowledges it may need partners to advance certain programs.1
- Approved autologous CAR T therapies
Products already marketed in later-line settings, referenced in the comparison of accessibility and logistics with allogeneic therapy.
- Allogeneic CAR T developers
Companies developing similar allogeneic products that may compete for patients and funding, not named in the sources provided.
- Gene-editing technology licensors
Suppliers of editing technologies under license to the company; not direct competitors, but they influence timelines and costs.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report02 Sept 2026Departure or appointment of officers
- Quarterly report12 Aug 2026
- Current report12 Aug 2026Results of operations · Financial statements and exhibits
- Current report22 Jun 2026Shareholder vote · Other events
- Current report28 May 2026Departure or appointment of officers
- Quarterly report13 May 2026
- Current report13 May 2026Material agreement · Termination of a material agreement · Results of operations · Financial statements and exhibits
- Proxy statement30 Apr 2026
- Current report15 Apr 2026Other events · Financial statements and exhibits
- Current report13 Apr 2026Other events
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Allogene Therapeutics, Inc. · 12 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Allogene Therapeutics, Inc. · 12 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Allogene Therapeutics, Inc. · 12 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.